This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Prostate Cancer
  • /
  • Docetaxel in prostate cancer: a familiar face as t...

Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.

Read time: 1 mins
Published:30th Apr 2017
Author: Puente J, Grande E, Medina A, Maroto P, Lainez N, Arranz JA.
Availability: Free full text
Ref.:Ther Adv Med Oncol. 2017;9(5):307-318.
The increasing knowledge of prostate cancer is leading to many questions about its natural history and to reconsider conventional therapeutic strategies. Androgen ablation therapy has been the standard therapy in the advanced setting. Although docetaxel has demonstrated increased survival in patients with metastatic prostate cancer who had progressed to hormone treatments, due to its potential toxicity the role of chemotherapy has been relegated to patients who were symptomatic or who had high tumor burden. Several studies have assessed whether docetaxel could have a role in hormone-sensitive disease or even in earlier stages with no distant metastases. In the CHAARTED and STAMPEDE studies, docetaxel provides an unprecedented increase in overall survival (OS). This review summarizes the evidence behind the paradigm shift to strengthening docetaxel as a new standard of treatment that prolongs survival in earlier stages of prostate cancer.

Read abstract on library site

Access full article